David Raben, MD, on NSCLC: Results From the PACIFIC Trial
2018 ASTRO Annual MeetingDavid Raben, MD, of the University of Colorado, discusses overall survival with durvalumab vs placebo after chemoradiotherapy in stage III non–small cell lung cancer (Abstract LBA10).
Related Videos
Vinai Gondi, MD, on Treating Brain Metastases, Preserving Cognitive Function
Vinai Gondi, MD, of Northwestern Medicine, discusses the early results of a phase III NRG Oncology trial that suggests a practice change in treating brain metastases: avoiding the ...
Howard M. Sandler, MD, on Prostate Cancer: Prospective Trials Update
Howard M. Sandler, MD, of Cedars-Sinai Medical Center, discusses a session on data from several long-term studies on localized disease, including optimal sequencing of radiation an...
Daniel E. Spratt, MD, on Prostate Cancer in African American Men: Results of a Meta-analysis
Daniel E. Spratt, MD, of the University of Michigan, discusses a large-scale gene-expression analysis and meta-analysis of RTOG trials on androgen receptor activity and radiotherap...
Howard M. Sandler, MD, on Localized Prostate Cancer: Radiation Therapy Guidelines
Howard M. Sandler, MD, of Cedars-Sinai Medical Center, summarizes a session he moderated that included discussion of an ASTRO, ASCO, and AUA guideline; indications and dose fractionation; treatment...
Daniel R. Gomez, MD, on NSCLC: Findings From a Phase II Treatment Trial
Daniel R. Gomez, MD, of The University of Texas MD Anderson Cancer Center, discusses the final results of a phase II study on local consolidative therapy, which improved overall su...
